Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs)
研究概览
简要总结
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy.
Approximately 30 people will take part in this study conducted by investigators at the University of Iowa.
详细描述
This is a single-arm open-label phase Ib and phase II clinical study assessing the safety and relative efficacy of concurrent talimogene laherparepvec in combination with radiotherapy in patients with soft tissue sarcomas. Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec. Weekly injections of talimogene laherparepvec will be continued until surgery. Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided informed consent.
- •Histologically confirmed diagnosis of locally advanced STS that is unresectable with clear wide margins, for which preoperative radiotherapy is considered appropriate.
- •Resectable stage IIB, III, and IV disease that are not suitable for surgically resection alone due to inability to achieve clear margins.
- •Including metastatic (stage IV) disease for which radiotherapy and surgical resection are indicated.
- •Except certain histologic subtypes: GIST, Desmoid, Ewing sarcoma, Kaposi sarcoma, and bone sarcomas.
- •Previous treatment: prior systemic anti-cancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy are allowed provided therapy completed at least 1 year prior to enrollment.
- •No prior Talimogene laherparepvec or tumor vaccines allowed.
- •No prior radiation to the same tumor bed allowed.
- •Age ≥18 years.
- •Both men and women of all races and ethnic groups are eligible for this trial.
- •ECOG performance status ≤
- •Patient must have measurable disease:
- •Tumor size at least ≥ 5 cm in the longest diameter as measured by CT scan or MRI for which radiation is feasible.
- •Patient must have injectable disease (direct injection or ultrasound guided).
排除标准
- •Certain histologic subtypes: GIST, Desmoid, Ewing sarcoma, Kaposi sarcoma, and bone sarcomas.
- •History or evidence of sarcoma associated with immunodeficiency states (e.g.: Hereditary immune deficiency, HIV, organ transplant or leukemia).
- •Subjects with retroperitoneal and visceral sarcoma.
- •History or evidence of gastrointestinal inflammatory bowel disease (ulcerative colitis or Crohn's disease) or other symptomatic autoimmune disease including, inflammatory bowel disease, or history of any poorly controlled or severe systemic autoimmune disease (i.e., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, type I diabetes, or autoimmune vasculitis).
- •History of other malignancy within the past 3 years except treated with curative intent and no known active disease present and has not received chemotherapy for ≥ 1 year before enrollment/randomization and low risk for recurrence.
- •History of prior or current autoimmune disease.
- •History of prior or current splenectomy or splenic irradiation.
- •Active herpetic skin lesions
- •Require intermittent or chronic treatment with an anti-herpetic drug (e.g., acyclovir), other than intermittent topical use.
- •Any non-oncology vaccine therapies used for the prevention of infectious disease within 28 days prior to enrollment and during treatment period.
- •Concomitant treatment with therapeutic anticoagulants such as warfarin.
- •Known human immunodeficiency virus (HIV) disease (requires negative test for clinically suspected HIV infection).
- •Acute or chronic hepatitis B or hepatitis C infection (requires negative test for clinically suspected hepatitis B or hepatitis C infection).
- •Evidence of hepatitis B -
- •Positive HBV surface antigen (indicative for chronic hepatitis B or recent acute hepatitis B).
- •Negative HBV surface antigen but positive HBV total core antibody (indicative for resolved hepatitis B infection or occult hepatitis B) and detectable copies of HBV DNA by PCR (detectable HBV DNA copies suggest occult hepatitis B).
- •Evidence of hepatitis C -
- •Positive HCV antibody and positive HCV RNA by PCR (undetectable RNA copies suggest past and resolved hepatitis C infection).
- •Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment.
- •Female subjects of childbearing potential or male subjects who are unwilling to use 2 highly effective methods of contraception during study treatment and through 3 months after the last dose of study treatment. See Section 7.5 for more details.
- •Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).
- •Other investigational procedures while participating in this study that could affect the primary objective of the study as determined by the PI are excluded.
- •Subject previously has entered this study.
- •Patients who are receiving any other investigational agents.
- •Evidence of CNS metastases.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients on or requiring immunosuppressive therapies.
- •Any of the following laboratory abnormalities:
- •Hemoglobin < 9.0 g/dL
- •Absolute neutrophil count (ANC) < 1500 per mm3
- •Platelet count < 100,000 per mm3
- •Total bilirubin > 1.5 × ULN
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN
- •Alkaline phosphatase > 2.5 × ULN
- •PT (or INR) and PTT (or aPTT) > 1.5 × ULN
- •Creatinine > 2.0 × ULN
研究组 & 干预措施
Treatment
Talimogene Laherparepvec in combination with radiotherapy
Talimogene Laherparepvec Dose Levels:
• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL
干预措施: Talimogene Laherparepvec (Drug)
Treatment
Talimogene Laherparepvec in combination with radiotherapy
Talimogene Laherparepvec Dose Levels:
• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs)
时间窗: 14 weeks
A DLT is defined as any of the following talimogene laherparepvec-related toxicity or related to the combination of talimogene laherparepvec and radiation therapy during treatment and up to 4 weeks after the last talimogene laherparepvec injection: Grade 3 or greater immune-mediated adverse events, Grade 3 or greater allergic reactions, any grade plasmacytoma, any other unexpected grade 3 or greater hematologic or non-hematologic toxicity, with the exceptions of: any grade of alopecia, expected radiation related skin toxicity of any grade, Grade 3 arthralgia or myalgia, brief (\< 1 week) grade 3 fatigue, Grade 3 fever, Grade 3 diarrhea or vomiting responding to supportive case.
Phase 2: Pathologic Tumor Necrosis Rate
时间窗: 14 weeks
Pathologic tumor necrosis rate is defined as the percentage of subjects with pathologic tumor necrosis ≥ 95%.
次要结局
- Overall Response Rate(24 months)
- Percentage of Participants With 2 Year Progression-Free Survival(24 months)
- Percentage of Participants With 2 Year Overall Survival(24 months)
- Number of Participants With Adverse Events (AEs)(14 weeks)
研究者
Mohammed Milhem
Clinical Professor
University of Iowa